Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm,
non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with
previously treated advanced radioactive-iodine refractory